Suchergebnisse

Metformin is one of the treatments used for pcoS pathology decreasing body weight, plasma androgen, FSH and glucose levels. Unfortunately, there is little known about metformin's effects on lipid metabolism, a crucial process in pcoS pathology. We have employed a lipidomic approach to explore alterations in the plasma lipid profile of patients with PCOS following metformin treatment. The aim is to offer new insights about the effect of metformin in PCOS patients. Plasma samples were obtained from 27 subjects prior to and following 12 weeks of metformin treatment. A detailed biochemical characterization and lipidomic profile was performed. Metformin reduces BMI, HOMA-IR, fSH and androstenedione and increases DHeA-S but no changes were found in glucose levels after treatment. Multivariate statistics revealed a specific lipidomic signature due to the effect of 12 weeks of metformin treatment in pcoS patients. this signature includes changes in sphingolipid metabolism suggesting a crosstalk between these lipid species and the androgenic metabolism and a decrease in oxidized lipids reinforcing that metformin treatment improves oxidative stress status. our study confirms the specific effect of metformin in lipid metabolism on women with PCOS after 12 weeks of treatment. ; We thank Maria Rosa Gomez and David Argiles for technical support. This research was funded by grants from Carlos III Health Institute (ISCIII) (PI16/1083, PI16/0301) to V.M.V and M.R, respectively and CIBERehd (CB06/04/0071)−initiatives of the ISCIII to M.R and V.M.V, the European Regional Development Fund (ERDF "A way to build Europe"). Unrestricted grant from Menarini S.A to M.R. V.M.V. and M.R. are recipients of contracts from the Ministry of Health of the Valencian Regional Government and Carlos III Health Institute (CES10/030 and CP10/0360, respectively). R. P. is recipient of contracts from the Spanish Ministry of Economy and Competitiveness, Institute of Health Carlos III (grant number PI14/00328); Spanish Ministry of Science, Innovation and Universities (grant number RTI2018-099200-B-I00), and the Generalitat of Catalonia, Department of Health (grant number SLT002/16/00250) and Department of Business and Knowledge (grant number 2017SGR696). This study has been co-financed by FEDER funds from the European Union ('A way to build Europe'). I.P. received a predoctoral fellowship from the Lleida University. S.R-LL. is recipient of a Juan de la Cierva contract from Spanish Ministry of Economy and Competitiveness (FJCI-2015-25040). C.B. is recipient of a Sara Borrell contract from Institute of Health Carlos III (CD14/00043). M.J is a Serra Húnter Fellow.

Purpose: In this work, a non-targeted approach was used to unravel changes in the plasma lipidome of PCOS patients. The aim is to offer new insights in PCOS patients strictly selected in order to avoid confounding factors such as dyslipemia, obesity, altered glucose/insulin metabolism, cardiovascular disease, or cancer. Results: Multivariate statistics revealed a specific lipidomic signature for PCOS patients without associated pathologies. This signature implies changes, mainly by down-regulation, in glycerolipid, glycerophospholipid and sphingolipid metabolism suggesting an altered biosynthetic pathway of glycerophospholipids and cell signaling as second messengers in women with PCOS. Conclusions: Our study confirms that a lipidomic approach discriminates a specific phenotype from PCOS women without associated pathologies from healthy controls. Methods: In a cross-sectional pilot study, data were obtained from 34 subjects, allocated to one of two groups: a) lean, healthy controls (n = 20), b) PCOS patients (n = 14) with diagnosis based on hyperandrogenaemia, oligo-anovulation and abnormal ovaries with small follicular cysts. A detailed biochemical characterization was made and lipidomic profiling was performed via an untargeted approach using LC-ESI-QTOF MS/MS. ; We acknowledge funding from the Fund for Health Research (FIS) and co-funding from the European Regional Development Fund of the European Union (FEDER, 'Una manera de hacer Europa'): PI15/1424, PI16/1083, PI16/0301 and UGP15-193 by FISABIO, to A.H.M, M.R. and V.M.V, respectively. This research was also in part funded by the Spanish Ministry of Economy and Competitiveness, Institute of Health Carlos III (FIS grants PI14/00328), and the Autonomous Government of Catalonia (2017SGR and SLT002/16/00250) to R.P. This study was co-financed by FEDER funds from the European Union ('Una manera de hacer Europa').